Literature DB >> 10155336

Multi-attribute preference functions. Health Utilities Index.

G W Torrance1, W Furlong, D Feeny, M Boyle.   

Abstract

Multi-attribute utility theory, an extension of conventional utility theory, can be applied to model preference scores for health states defined by multi-attribute health status classification systems. The type of preference independence among the attributes determines the type of preference function required: additive, multiplicative or multilinear. In addition, the type of measurement instrument used determines the type of preference score obtained: value or utility. Multi-attribute utility theory has been applied to 2 recently developed multi-attribute health status classification systems, the Health Utilities Index (HUI) Mark II and Mark III systems. Results are presented for the Mark II system, and ongoing research is described for the Mark III system. The theory is also discussed in the context of other well known multi-attribute systems. The HUI system is an efficient method of determining a general public-based utility score for a specified health outcome or for the health status of an individual. In clinical populations, the scores can be used to provide a single summary measure of health-related quality of life. In cost-utility analyses, the scores can be used as quality weights for calculating quality-adjusted life years. In general populations, the measure can be used as quality weights for determining population health expectancy.

Mesh:

Year:  1995        PMID: 10155336     DOI: 10.2165/00019053-199507060-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  36 in total

1.  The National Population Health Survey: highlights of initial developments.

Authors:  G Catlin; P Will
Journal:  Health Rep       Date:  1992       Impact factor: 4.796

2.  Principles of cost-effective resource allocation in health care organizations.

Authors:  M C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  1990       Impact factor: 2.188

3.  A multiattribute approach to health-status measurement and clinical management illustrated by an application to brain-tumors in childhood.

Authors:  R Barr; M Pai; S Weitzman; D Feeny; W Furlong; P Rosenbaum; G Torrance
Journal:  Int J Oncol       Date:  1994-03       Impact factor: 5.650

Review 4.  Utility approach to measuring health-related quality of life.

Authors:  G W Torrance
Journal:  J Chronic Dis       Date:  1987

5.  Technology assessment and cost-effectiveness analysis: misguided guidelines?

Authors:  C D Naylor; J I Williams; A Basinski; V Goel
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

6.  Economic evaluation of neonatal intensive care of very-low-birth-weight infants.

Authors:  M H Boyle; G W Torrance; J C Sinclair; S P Horwood
Journal:  N Engl J Med       Date:  1983-06-02       Impact factor: 91.245

7.  Developing multiattribute health indexes.

Authors:  M H Boyle; G W Torrance
Journal:  Med Care       Date:  1984-11       Impact factor: 2.983

8.  Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

Review 9.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

10.  The comprehensive assessment of health status in survivors of childhood cancer: application to high-risk acute lymphoblastic leukaemia.

Authors:  D Feeny; A Leiper; R D Barr; W Furlong; G W Torrance; P Rosenbaum; S Weitzman
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

View more
  119 in total

1.  The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life.

Authors:  G Hawthorne; J Richardson; R Osborne
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

Review 2.  A comparative review of generic quality-of-life instruments.

Authors:  S J Coons; S Rao; D L Keininger; R D Hays
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

3.  Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication.

Authors:  J L Bosch; M G Hunink
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

4.  Valuation of EuroQOL (EQ-5D) health states in an adult US sample.

Authors:  J A Johnson; S J Coons; A Ergo; G Szava-Kovats
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

5.  Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the Health Utilities Index.

Authors:  D G Manuel; S E Schultz; J A Kopec
Journal:  J Epidemiol Community Health       Date:  2002-11       Impact factor: 3.710

6.  Accuracy of a decision aid for advance care planning: simulated end-of-life decision making.

Authors:  Benjamin H Levi; Steven R Heverley; Michael J Green
Journal:  J Clin Ethics       Date:  2011

7.  Cost-effectiveness of automated external defibrillator deployment in selected public locations.

Authors:  Peter Cram; Sandeep Vijan; A Mark Fendrick
Journal:  J Gen Intern Med       Date:  2003-09       Impact factor: 5.128

Review 8.  Quality of life assessment in gastro-oesophageal reflux disease.

Authors:  E J Irvine
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Impact of impairment and secondary health conditions on health preference among Canadians with chronic spinal cord injury.

Authors:  Catharine Craven; Sander L Hitzig; Nicole Mittmann
Journal:  J Spinal Cord Med       Date:  2012-09       Impact factor: 1.985

10.  Valuing benefits to inform a clinical trial in pharmacy : do differences in utility measures at baseline affect the effectiveness of the intervention?

Authors:  Michela Tinelli; Mandy Ryan; Christine Bond; Anthony Scott
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.